secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001564590-21-042879
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q2 net loss $15.2M; cash $168.1M; Takeda accelerates UC program
--------------------------------------------------------------------------------

- Net loss $15.2M vs $8.3M YoY; R&D expense $14.0M, G&A $5.9M.
- Cash and equivalents $168.1M at June 30, 2021, expected to fund operations into mid-2023.
- Takeda elected to accelerate leadership of FIN-524/TAK-524 ulcerative colitis program.
- CP101 open-label PRISM-EXT topline data from >130 patients expected H2 2021.
- Topline data from FIN-211 in ASD and CP101 in chronic HBV expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/0001564590-21-042879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/fnch-8k_20210810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-042879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer